Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Roche's Autogene cevumeran?
Autogene cevumeran is a mrna vaccine commercialized by Roche, with a leading Phase II program in Triple-Negative Breast Cancer (TNBC)....
Autogene cevumeran by Genentech USA for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Autogene cevumeran is under clinical development by Genentech USA and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...
Risk adjusted net present value: What is the current valuation of F. Hoffmann-La Roche's Autogene cevumeran?
Autogene cevumeran is a mrna vaccine commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Triple-Negative Breast...
Autogene cevumeran by Genentech USA for Solid Tumor: Likelihood of Approval
Autogene cevumeran is under clinical development by Genentech USA and currently in Phase II for Solid Tumor. According to GlobalData,...